News

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.

West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C

Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call

West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

The companies you own inside this consumer staples fund are collectively signaling stronger profits are on the way.

West Pharmaceutical Services will release its second-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Cooper Companies beats Q2 EPS and sales estimates as CooperVision and CooperSurgical hit record revenues, even with a GAAP loss from recall litigation.